These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29549158)

  • 1. AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNF
    Pehrson R; Hegelund-Myrbäck T; Cunoosamy D; Asimus S; Jansson P; Patel N; Borde A; Lundin S
    J Pharmacol Exp Ther; 2018 Jun; 365(3):567-572. PubMed ID: 29549158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
    Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells.
    Higham A; Karur P; Jackson N; Cunoosamy DM; Jansson P; Singh D
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1279-1288. PubMed ID: 29719383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glabridin reduces lipopolysaccharide-induced lung injury in rats by inhibiting p38 mitogen activated protein kinase/extracellular regulated protein kinases signaling pathway].
    Zhang LP; Li JG
    Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3893-3897. PubMed ID: 28057160
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects.
    Singh D; Siew L; Christensen J; Plumb J; Clarke GW; Greenaway S; Perros-Huguet C; Clarke N; Kilty I; Tan L
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1175-84. PubMed ID: 26265232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway.
    Liu S; Feng G; Wang GL; Liu GJ
    Eur J Pharmacol; 2008 Apr; 584(1):159-65. PubMed ID: 18328478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
    Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
    Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway.
    Yoshinari D; Takeyoshi I; Koibuchi Y; Matsumoto K; Kawashima Y; Koyama T; Ohwada S; Morishita Y
    Crit Care Med; 2001 Mar; 29(3):628-34. PubMed ID: 11373433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species.
    Fehr S; Unger A; Schaeffeler E; Herrmann S; Laufer S; Schwab M; Albrecht W
    Cell Physiol Biochem; 2015; 36(6):2237-49. PubMed ID: 26279429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model.
    Rogers JE; Li F; Coatney DD; Otremba J; Kriegl JM; Protter TA; Higgins LS; Medicherla S; Kirkwood KL
    J Periodontol; 2007 Oct; 78(10):1992-8. PubMed ID: 18062121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.
    Raubo P; Evans R; Willis P
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127412. PubMed ID: 32717614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor progression locus 2 protein kinase decreases lipopolysaccharide-induced tumor necrosis factor alpha production due to the inhibition of the tip-associated protein induction in RAW264.7 cells.
    Hirata K; Miyashiro M; Ogawa H; Taki H; Tobe K; Sugita T
    Biol Pharm Bull; 2010; 33(7):1233-7. PubMed ID: 20606319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
    Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
    Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat.
    Wu CC; Thiemermann C; Vane JR
    Br J Pharmacol; 1995 Mar; 114(6):1273-81. PubMed ID: 7542532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha.
    Wadsworth TL; McDonald TL; Koop DR
    Biochem Pharmacol; 2001 Oct; 62(7):963-74. PubMed ID: 11543732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.